Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for VBI Vaccines, Inc. (VBIV : NSDQ)

• Company Description    VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. Number of Employees: 155

• Price / Volume Information    Yesterday's Closing Price: $1.04 Daily Weekly Monthly 20 Day Moving Average: 2,085,609 shares Shares Outstanding: 258.26 (millions) Market Capitalization: $268.59 (millions) Beta: 2.01 52 Week High: $4.31 52 Week Low: $0.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.77% -21.95% 12 Week -25.71% -19.40% Year To Date -55.56% -47.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 160 Second Street Floor 3 - Cambridge,MA 02142 USA ph: 617-830-3031 fax: - ir@vbivaccines.com http://www.vbivaccines.com

• General Corporate Information    Officers Jeffrey Baxter - Chief Executive Officer and President Christopher McNulty - Chief Financial Officer and Head of Business Devel Steven Gillis - Director Michel De Wilde - Director Blaine McKee - Director Peer Information VBI Vaccines, Inc. (CORR.) VBI Vaccines, Inc. (RSPI) VBI Vaccines, Inc. (CGXP) VBI Vaccines, Inc. (BGEN) VBI Vaccines, Inc. (GTBP) VBI Vaccines, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 91822J103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/01/22 Share - Related Items Shares Outstanding: 258.26 Most Recent Split Date: (:1) Beta: 2.01 Market Capitalization: $268.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/01/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.07 Price/Cash Flow: - Price / Sales: 589.01 EPS Growth vs. Year Ago Period: -14.29% vs. Previous Quarter: -14.29% Sales Growth vs. Year Ago Period: -58.14% vs. Previous Quarter: 55.56% ROE 03/31/22 - -48.77 12/31/21 - -42.79 09/30/21 - -39.02 ROA 03/31/22 - -34.40 12/31/21 - -31.63 09/30/21 - -30.11 Current Ratio 03/31/22 - 3.31 12/31/21 - 4.00 09/30/21 - 4.49 Quick Ratio 03/31/22 - 3.19 12/31/21 - 3.92 09/30/21 - 4.42 Operating Margin 03/31/22 - -16,087.72 12/31/21 - -11,054.36 09/30/21 - -9,290.20 Net Margin 03/31/22 - -16,087.72 12/31/21 - -11,054.36 09/30/21 - -9,290.20 Pre-Tax Margin 03/31/22 - -16,087.72 12/31/21 - -11,054.36 09/30/21 - -9,290.20 Book Value 03/31/22 - 0.50 12/31/21 - 0.56 09/30/21 - 0.63 Inventory Turnover 03/31/22 - 4.09 12/31/21 - 4.80 09/30/21 - 4.65 Debt-to-Equity 03/31/22 - 0.19 12/31/21 - 0.20 09/30/21 - 0.17 Debt-to-Capital 03/31/22 - 16.06 12/31/21 - 16.50 09/30/21 - 14.85

Powered by Zacks Investment Research ©